Kevin Kinsella, founder of Avalon Ventures, primarily invests in early-stage (seed and Series A) companies within. See sector focus and contact routes.
Kevin Kinsella, founder of Avalon Ventures, primarily invests in early-stage (seed and Series A) companies within biotechnology, life sciences, and information technology (including wireless communications and digital media). His notable portfolio includes founding investments in publicly traded firms like Vertex Pharmaceuticals, Onyx Pharmaceuticals, and Synaptics, as well as high-profile exits such as Zynga (which generated a $340 million return) and Synthorx (acquired by Sanofi for $2.5 billion). Kinsella’s distinctive thesis centers on incubating companies from inception and leveraging his own entrepreneurial background to support founders building disruptive therapeutics, diagnostics, and medical devices.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in La Jolla when building a target list.
Investors like Kevin Kinsella · Full investor directory · Investor access · Company funding database